Global and Japan Recombinant Erythropoietin Drugs Market Insights, Forecast to 2027

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.

Market Analysis and Insights: Global and Japan Recombinant Erythropoietin Drugs Market
This report focuses on global and Japan Recombinant Erythropoietin Drugs market.
In 2020, the global Recombinant Erythropoietin Drugs market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Recombinant Erythropoietin Drugs market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Recombinant Erythropoietin Drugs Scope and Market Size
Recombinant Erythropoietin Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Erythropoietin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Recombinant Erythropoietin Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)

Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd